Mikkel Hojlund (Mikkel Højlund, M Højlund)

Scopus Author ID Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 26

Top Venues

Acta neuropsychiatrica

Basic & clinical pharmacology & toxicology

Expert opinion on investigational drugs

British journal of clinical pharmacology

Odense University Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Odense University Hospital

Denmark

Research Assistant :: Department of Oncology

Mental Health Services Region of Southern Denmark Aug 01 2016

Denmark

Research Associate :: Department of Psychiatry Aabenraa

Publications

Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Hojlund, Joseph Firth, Dan J Siskind, Richard Ig Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review. Expert opinion on drug safety (2024)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica (2023)
Marie Krab Lund, Mikkel Hojlund, Lars Christian Lund
Smoking and severe mental illness: Drawing inference on the directionality of the association requires careful consideration of the temporality of the data. Acta psychiatrica Scandinavica (2023)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica 35 (1) (2023)
Marco Solmi, Samuele Cortese, Giovanni Vita, Michele De Prisco, Joaquim Radua, Elena Dragioti, Ole Köhler-Forsberg, Nanna M Madsen, Christopher Rohde, Luis Eudave, Claudia Aymerich, Borja Pedruzo, Victoria Rodriguez, Stella Rosson, Michel Sabé, Mikkel Hojlund, Ana Catalan, Beatrice de Luca, Michele Fornaro, Giovanni Ostuzzi, Corrado Barbui, Gonzalo Salazar-de-Pablo, Paolo Fusar-Poli, Christoph U Correll
An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders. Molecular psychiatry (2023)
Mikkel Hojlund, Christoph U Correll
Switching to Long-Acting Injectable Antipsychotics: Pharmacological considerations and practical approaches. Expert opinion on pharmacotherapy (2023)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica 35 (1) (2023)
Mikkel Hojlund, Kjeld Andersen, Martin T Ernst, Christoph U Correll, Jesper Hallas
Re: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica (2023)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica 35 (1) (2023)
Mikkel Hojlund, Jane Sterndorff Winkel, Mads Nybo, Nina Sahlertz Kristiansen, Daniel Pilsgaard Henriksen, Per Damkier
Lithium and the risk of chronic kidney disease: A population-based case-control study. Basic & clinical pharmacology & toxicology 131 (2) (2022)
Mikkel Hojlund, Christoph U Correll
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert opinion on investigational drugs 31 (12) (2022)
Mikkel Hojlund, Lárus Steinþór Guðmundsson, Jacob Harbo Andersen, Leena K Saastamoinen, Helga Zoega, Svetlana Ondrasova Skurtveit, Jonas W Wastesson, Nina Sahlertz Kristiansen, Jesper Hallas
Use of benzodiazepines and benzodiazepine-related drugs in the Nordic countries between 2000 and 2020. Basic & clinical pharmacology & toxicology (2022)
Mikkel Hojlund, Lotte Rasmussen, Morten Olesen, Trine Munk-Olsen, Jesper Hallas
Who prescribes quetiapine in Denmark? British journal of clinical pharmacology 88 (9) (2022)
Mikkel Hojlund, Christoph U Correll
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert opinion on investigational drugs 31 (12) (2022)
Mikkel Hojlund, Eeva-Liisa Røssell Johansen, Kjeld Andersen, Christoph U Correll, Nina Sahlertz Kristiansen
Impact of low-dose quetiapine-use on glycosylated hemoglobin, triglyceride and cholesterol levels. Acta psychiatrica Scandinavica (2022)
Mikkel Hojlund, Christoph U Correll
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert opinion on investigational drugs 31 (12) (2022)
Mikkel Hojlund, Christoph U Correll
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert opinion on investigational drugs (2022)
Christopher Rohde, Mikkel Hojlund, Christiane Gasse, Jesper Hallas, Ole Köhler-Forsberg
Free-of-charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications. Basic & clinical pharmacology & toxicology 131 (4) (2022)
Mikkel Hojlund, Christina Blanner Kristiansen, Rikke Wesselhoeft, Kjeld Andersen, Anders Fink-Jensen, Nina Sahlertz Kristiansen
Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study. Basic & clinical pharmacology & toxicology 130 (4) (2022)
Mikkel Hojlund, Jacob Harbo Andersen, Kjeld Andersen, Christoph U Correll, Nina Sahlertz Kristiansen
Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses. Epidemiology and psychiatric sciences 30 (2021)
Casper Falster, Niels Jacobsen, Karen Ehlers Coman, Mikkel Hojlund, Thomas Agerbo Gaist, Stefan Posth, Jacob Eifer Moller, Mikkel Brabrand, Christian Borbjerg Laursen
Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis. Thorax (2021)
Mikkel Hojlund, Lars Christian Lund, Jonas Leander Emming Herping, Maija Bruun Haastrup, Per Damkier, Daniel Pilsgaard Henriksen
Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study. BMJ open 10 (8) (2020)
Mikkel Hojlund, Jesper Hallas, Erik Johnsen, Rune A Kroken, Johan Reutfors, Povl Munk-Jørgensen, Christoph U Correll
Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. British journal of clinical pharmacology 85 (7) (2019)
Mikkel Hojlund, Lene Høgh, Anders Bo Bojesen, Povl Munk-Jørgensen, Elsebeth Stenager
Use of antipsychotics and benzodiazepines in connection to minimising coercion and mechanical restraint in a general psychiatric ward. The International journal of social psychiatry 64 (3) (2018)
Mikkel Hojlund, Pia Hansen, Willy Krone, Lene Høgh
Obstructive hydrocephalus caused by colloid cyst presenting as a schizophrenia-like psychosis. BMJ case reports 2018 (2018)
Mikkel Hojlund, Anja Friis Elliott, Nikolaj Juul Madsen, Anne Grethe Viuff, Povl Munk-Jørgensen, Peter Hjorth
Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia. Nordic journal of psychiatry 71 (8) (2017)

Mikkel Hojlund.css-eqlu8i{font-size:small;padding-left:4px;} (Mikkel Højlund, M Højlund)

Publication Activity (10 Years)

Top Topics

Top Venues

Mikkel Hojlund (Mikkel Højlund, M Højlund)